Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.44 |
| ▸ | PARP1 | P09874 | 4/20 | 0.42 |
| ▸ | HRH1 | P35367 | 10/20 | 0.42 |
| ▸ | CCR3 | P51677 | 10/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8937109 | 0.95 | HTR6 (0.45) | HRH3OPRK1ROCK1PARP1HRH1 | |
| SCHEMBL8937004 | 0.88 | PARP1 (0.54) | HRH3ROCK1PARP1HRH1CCR3 | |
| SCHEMBL8935114 | 0.88 | ROCK1 (0.58) | HRH3OPRK1ROCK1PARP1HRH1 | |
| SCHEMBL8934534 | 0.86 | MAOA (0.50) | HRH3ROCK1PARP1HRH1CCR3 | |
| SCHEMBL8936996 | 0.86 | MAOA (0.58) | HRH3ROCK1PARP1HRH1CCR3 | |
| SCHEMBL8937018 | 0.86 | HRH3 (0.48) | HRH3ROCK1PARP1HRH1CCR3 | |
| SCHEMBL8937140 | 0.84 | MAOA (0.57) | HRH3OPRK1ROCK1PARP1HRH1 | |
| SCHEMBL8937077 | 0.84 | PARP1 (0.55) | ROCK1PARP1HRH1CCR3KCNH2 | |
| SCHEMBL8937147 | 0.83 | MAOA (0.51) | HRH3ROCK1PARP1HRH1CCR3 | |
| SCHEMBL8937068 | 0.83 | ROCK1 (0.44) | ROCK1PARP1HRH1CCR3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-8188117-B2 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2385047-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI (FR) | 2011-11-09 | — | — | EP | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | SANOFI-AVENTIS (FR) | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093518-A1 | Piperidinyl-substituted isoquinolone derivatives | MYLK2, MYLK, RHOT2 | HRH3 3637/4885OPRK1 2154/4885ROCK1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.